Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344

Katrine Wickstroem(Bayer (Norway)), Alan Cuthbertson(Bayer (Norway))
International Journal of Radiation Oncology*Biology*Physics
June 27, 2019
10.1016/j.ijrobp.2019.06.2508
Cited by 27

Related Papers

Synergistic Effect of a Mesothelin-Targeted <sup>227</sup>Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
|Journal of Nuclear Medicine|2019|51